Meta-Analysis of Anti-Toxoplasma gondii IgM Antibodies in Acute Psychosis

Schizophrenia Bulletin

Volumn 41, Issue 4, 2015, Pages 989-998

  Monroe, Joel M ^a   Buckley, Peter F ^a   Miller, Brian J ^a  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

infection; meta analysis; psychosis; relapse; toxoplasmosis

Indexed keywords

IMMUNOGLOBULIN M ANTIBODY; TOXOPLASMA GONDII IMMUNOGLOBULIN M ANTIBODY; UNCLASSIFIED DRUG; IMMUNOGLOBULIN M; PROTOZOON ANTIBODY;

ACUTE PSYCHOSIS; ARTICLE; DISEASE ASSOCIATION; GEOGRAPHIC ORIGIN; HUMAN; META ANALYSIS; NONHUMAN; PRIORITY JOURNAL; PUBLICATION; RELAPSE; RISK FACTOR; SCHIZOPHRENIA; SERUM; SYSTEMATIC REVIEW; TOXOPLASMA GONDII; BLOOD; IMMUNOLOGY; PSYCHOSIS; TOXOPLASMA; TOXOPLASMOSIS;

ANTIBODIES, PROTOZOAN; HUMANS; IMMUNOGLOBULIN M; PSYCHOTIC DISORDERS; SCHIZOPHRENIA; TOXOPLASMA; TOXOPLASMOSIS;

EID: 84936745168     PISSN: 05867614     EISSN: 17451701     Source Type: Journal    
DOI: 10.1093/schbul/sbu159     Document Type: Article

References (69)

1. Brown AS, Derkits EJ. Prenatal infection and schizophrenia: A review of epidemiologic and translational studies. Am J Psychiatry. 2010;167:261-280.
2. Clarke MC, Tanskanen A, Huttunen M, Whittaker JC, Cannon M. Evidence for an interaction between familial liability and prenatal exposure to infection in the causation of schizophrenia. Am J Psychiatry. 2009;166:1025-1030.
3. Nielsen PR, Benros ME, Mortensen PB. Hospital contacts with infection and risk of schizophrenia: A populationbased cohort study with linkage of danish national registers. Schizophr Bull. 2014;40:1526-1532.
4. Saha S, Chant D, McGrath J. A systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time? Arch Gen Psychiatry. 2007;64:1123-1131.
5. Brown S, Kim M, Mitchell C, Inskip H. Twenty-five year mortality of a community cohort with schizophrenia. Br J Psychiatry. 2010;196:116-121.
6. Brendel RW, Stern TA. Psychotic symptoms in the elderly. Prim Care Companion J Clin Psychiatry. 2005;7:238-241.
7. Webster J, Grossberg GT. Late-life onset of psychotic symptoms. Am J Geriatr Psychiatry. 1998;6:196-202.
8. Robinson D, Woerner MG, Alvir JM, et al. Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Arch Gen Psychiatry. 1999;56:241-247.
9. Müller N, Riedel M, Scheppach C, et al. Beneficial antipsychotic effects of celecoxib add-on therapy compared to risperidone alone in schizophrenia. Am J Psychiatry. 2002;159:1029-1034.
10. Shepherd M, Watt D, Falloon I, Smeeton N. The natural history of schizophrenia: A five-year follow-up study of outcome and prediction in a representative sample of schizophrenics. Psychol Med Monogr Suppl. 1989;15:1-46.
11. Wyatt RJ. Early intervention with neuroleptics may decrease the long-term morbidity of schizophrenia. Schizophr Res. 1991;5:201-202.
12. Torrey EF, Bartko JJ, Lun ZR, Yolken RH. Antibodies to Toxoplasma gondii in patients with schizophrenia: A metaanalysis. Schizophr Bull. 2007;33:729-736.
13. Amminger GP, McGorry PD, Berger GE, et al. Antibodies to infectious agents in individuals at ultra-high risk for psychosis. Biol Psychiatry. 2007;61:1215-1217.
14. Duffy KT, Wharton PJ, Johnson JD, New L, Holliman RE. Assessment of immunoglobulin-M immunosorbent agglutination assay (ISAGA) for detecting toxoplasma specific IgM. J Clin Pathol. 1989;42:1291-1295.
15. Dzitko K, Staczek P, Gatkowska J, Dlugonska H. Toxoplasma gondii: serological recognition of reinfection. Exp Parasitol. 2006;112:134-137.
16. Giraldo M, Portela RW, Snege M, et al. Immunoglobulin M (IgM)-glycoinositolphospholipid enzyme-linked immunosorbent assay: an immunoenzymatic assay for discrimination between patients with acute toxoplasmosis and those with persistent parasite-specific IgM antibodies. J Clin Microbiol. 2002;40:1400-1405.
17. Hassan M, Hegab M, Abaza BE, Nasr ME, Mowafy NM. Specific anti-Toxoplasma antibodies in relation to infection and reinfection using different infective stages. J Egypt Soc Parasitol. 1999;29:119-129.
18. Sharma SD, Mullenax J, Araujo FG, Erlich HA, Remington JS. Western blot analysis of the antigens of Toxoplasma gondii recognized by human IgM and IgG antibodies. J Immunol. 1983;131:977-983.
19. Alvarado-Esquivel C, Alanis-Quiñones OP, Arreola-Valenzuela MA, et al. Seroepidemiology of Toxoplasma gondii infection in psychiatric inpatients in a northern Mexican city. BMC Infect Dis. 2006;6:178-184.
20. Alvarado-Esquivel C, Urbina-Álvarez JD, Estrada-Martínez S, et al. Toxoplasma gondii infection and schizophrenia: A case control study in a low Toxoplasma seroprevalence Mexican population. Parasitol Int. 2011;60:151-155.
21. Cetinkaya Z, Yazar S, Gecici O, Namli MN. Anti-Toxoplasma gondii antibodies in patients with schizophrenia-preliminary findings in a Turkish sample. Schizophr Bull. 2007;33:789-791.
22. Daryani A, Mehdi S, Sayed HH, Sayed AK, Shirzad G: Serological survey of Toxoplasma gondii in schizophrenia patients referred to Psychiatric Hospital, Sari City, Iran. Trop Biomed. 2010;27:476-482.
23. Dogruman-Al F, Aslan S, Yalcin S, Kustimu S, Turk S. A possible relationship between Toxoplasma gondii and schizophrenia: A seroprevalence study. Int J Psychiatr Clin Pract. 2009;13:82-87.
24. Hamidinejat H, Ghorbanpoor M, Hosseini H, et al. Toxoplasma gondii infection in first-episode and inpatient individuals with schizophrenia. Int J Infect Dis. 2010;14:e978-e981.
25. Krause D, Matz J, Weidinger E, et al. The association of infectious agents and schizophrenia. World J Biol Psychiatry. 2010;11:739-743.
26. Liu M, Want T, Li H, et al. Analysis of the antibodies anti-Toxoplasma gondii by ELISA based on two diagnostic antigens: rSAG1 and rBAG1. Acta Parasitologica. 2011;56:353-359.
27. Mahmoud SS, Hasan MS: Seroprevalence of toxoplasmosis among Schizophrenic patients. Yemeni J Med Sci. 2009;1:1-7.
28. Tamer GS, Dundar D, Yalug I, Caliskan S, Yazar S, Aker A. The schizophrenia and Toxoplasma gondii connection: infectious, immune or both? Adv Ther. 2008;25:703-709.
29. Yuksel P, Alpay N, Babur C, et al. The role of latent toxoplasmosis in the aetiopathogenesis of schizophrenia-The risk factor or an indication of a contact with cat? Folia Parasitol (Praha). 2010;57:121-128.
30. Saraei-Sahnesaraei MS, Shamloo F, Hashemi HJ, Khabbaz F, Alizadeh S-A. Relation between Toxoplasma gondii infections and schizophrenia. Iranian J Psychiatr Clin Psychol. 2009;15:3-9.
31. James BO, Agbonile IO, Okolo M, Lawani AO, Omoaregba JO. Prevalence of Toxoplasma gondii infection among individuals with severe mental illness in Nigeria: A case control study. Pathog Glob Health. 2013;107:189-193.
32. Tanyuksel M, Uzun O, Araz E, Koru O, Babur C. Possible role of toxoplasmosis in patients with first-episode schizophrenia. Turk J Med Sci. 2010;40:399-404.
33. Wang HL, Wang GH, Li QY, Shu C, Jiang MS, Guo Y. Prevalence of Toxoplasma infection in first-episode schizophrenia and comparison between Toxoplasma-seropositive and Toxoplasma-seronegative schizophrenia. Acta Psychiatr Scand. 2006;114:40-48.
34. Yolken RH, Bachmann S, Ruslanova I, et al. Antibodies to Toxoplasma gondii in individuals with first-episode schizophrenia. Clin Infect Dis. 2001;32:842-844.
35. Bachmann S, Schr?der J, Bottmer C, Torrey EF, Yolken RH. Psychopathology in first-episode schizophrenia and antibodies to Toxoplasma gondii. Psychopathology. 2005;38:87-90.
36. Dickerson F, Stallings C, Origoni A, et al. A combined marker of inflammation in individuals with mania. PLoS One. 2013;8:e73520.
37. Dickerson F, Stallings C, Origoni A, et al. Antibodies to Toxoplasma gondii in individuals with mania. Bipolar Disorders. 2014;16:129-136.
38. Hinze-Selch D, Däubener W, Erdag S, Wilms S: The diagnosis of personality disorder increases the likelihood of seropositivity to Toxoplasma gondii in psychiatric patients. Folia Parasitologica. 2010;57:129-135.
39. Hinze-Selch D, Däubener W, Eggert L, Erdag S, Stoltenberg R, Wilms S. A controlled prospective study of Toxoplasma gondii infection in individuals with schizophrenia: beyond seroprevalence. Schizophr Bull. 2007;33:782-788.
40. Holub D, Flegr J, Dragomirecká E, et al. Differences in onset of disease and severity of psychopathology between toxoplasmosis-related and toxoplasmosis-unrelated schizophrenia. Acta Psychiatr Scand. 2013;127:227-238.
41. Juanah LY, Jalaludin J, Osman M, Osman ZJ: Seroprevalence of Toxoplasma gondii among schizophrenics at Hospital Kajang. Am J Infect Diseases. 2013;9:11-16.
42. Leweke FM, Gerth CW, Koethe D, et al. Antibodies to infectious agents in individuals with recent onset schizophrenia. Eur Arch Psychiatry Clin Neurosci. 2004; 254:4-8.
43. Ling WH, Wang GH, Li QY, Shu C, Jiang MS, Guo Y. Prevalence of toxoplasma infection in first-episode schizophrenia and comparison between toxoplasma-positive and toxoplasma-negative schizophrenia. Schizophr Bull. 2005;31: 203-204.
44. Nascimento FS, de Rosalmeida Dantas C, Netto MP, et al. Prevalence of antibodies to Toxoplasma gondii in patients with schizophrenia and mood disorders. Schizophr Res. 2012;142:244-245.
45. Niebuhr DW, Millikan AM, Cowan DN, Yolken R, Li Y, Weber NS. Selected infectious agents and risk of schizophrenia among U.S. military personnel. Am J Psychiatry. 2008;165:99-106.
46. Yonghua Z, Yue C, Lei Z, Qi G: Analysis of probable correlation between Toxoplasma gondii and schizophrenia: A seroepidemiological longitudinal investigation from 2002 to 2007 in Suzhou and Wuxi regions, Jiangsu, China. Trop Med Int Health. 2011;16:367.
47. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177-188.
48. National Research Council. Combining Information: Statistical Issues and Opportunities for Research. Washington, DC: National Academy Press; 1992.
49. Field AP. Meta-analysis of correlation coefficients: A Monte Carlo comparison of fixed-and random-effects methods. Psychol Methods. 2001;6:161-180.
50. Hunter J, Schmidt F. Fixed effects vs. random effects metaanalysis models: implications for cumulative research knowledge. Int J Selection Assess. 2000;8:275-292.
51. Cochran WB. The comparison of percentages in matched samples. Biometrika. 1950;37:256-266.
52. Song F, Sheldon TA, Sutton AJ, Abrams KR, Jones DR. Methods for exploring heterogeneity in meta-analysis. Eval Health Prof. 2001;24:126-151.
53. Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011].9. Sensitivity analyses. The Cochrane Collaboration, 2011. www.cochrane-handbook.org.
54. Sterne JAC, Egger M. Funnel plots for detecting bias in meta-analysis: guidelines on choice of axis. J Clin Epidemiol. 2001;54:1046-1055.
55. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. Br Med J. 1997;315:629-634.
56. StataCorp. Stata Statistical Software: Release 10. College Station, TX: StataCorp LP; 2007.
57. Chiang TY, Hsieh HH, Kuo MC, et al. Seroepidemiology of Toxoplasma gondii infection among healthy blood donors in Taiwan. PLoS One. 2012;7:e48139.
58. Mosti M, Pinto B, Giromella A, et al. A 4-year evaluation of toxoplasmosis seroprevalence in the general population and in women of reproductive age in central Italy. Epidemiol Infect. 2013;141:2192-2195.
59. Alvarado-Esquivel C, Estrada-Martínez S, Pizarro-Villalobos H, Arce-Quiñones M, Liesenfeld O, Dubey JP. Seroepidemiology of Toxoplasma gondii infection in general population in a northern Mexican city. J Parasitol. 2011;97:40-43.
60. Svobodová V, Literák I. Prevalence of IgM and IgG antibodies to Toxoplasma gondii in blood donors in the Czech Republic. Eur J Epidemiol. 1998;14:803-805.
61. Ogoina D, Onyemelukwe GC, Musa BO, Obiako RO. Seroprevalence of IgM and IgG antibodies to Toxoplasma infection in healthy and HIV-positive adults from Northern Nigeria. J Infect Dev Ctries. 2013;7:398-403.
62. Moncada PA, Montoya JG. Toxoplasmosis in the fetus and newborn: an update on prevalence, diagnosis and treatment. Expert Rev Anti Infect Ther. 2012;10:815-828.
63. Flegr J, Prandota J, Sovičková M, Israili ZH. Toxoplasmosis-A global threat. Correlation of latent toxoplasmosis with specific disease burden in a set of 88 countries. PLoS One. 2014;9:e90203.
64. Morisset S, Peyron F, Lobry JR, et al. Serotyping of Toxoplasma gondii: striking homogeneous pattern between symptomatic and asymptomatic infections within Europe and South America. Microbes Infect. 2008;10:742-747.
65. Miller BJ, Graham KL, Bodenheimer CM, Culpepper NH, Waller JL, Buckley PF. A prevalence study of urinary tract infections in acute relapse of schizophrenia. J Clin Psychiatry. 2013;74:271-277.
66. Graham KL, Carson CM, Ezeoke A, Buckley PF, Miller BJ. Urinary tract infections in acute psychosis. J Clin Psychiatry. 2014;75:379-385.
67. Srikanth S, Ravi V, Poornima KS, Shetty KT, Gangadhar BN, Janakiramaiah N. Viral antibodies in recent onset, nonorganic psychoses: correspondence with symptomatic severity. Biol Psychiatry. 1994;36:517-521.
68. Fellerhoff B, Laumbacher B, Mueller N, Gu S, Wank R. Associations between Chlamydophila infections, schizophrenia and risk of HLA-A10. Mol Psychiatry. 2007;12:264-272.
69. Ahokas A, Rimón R, Koskiniemi M, Vaheri A, Julkunen I, Sarna S. Viral antibodies and interferon in acute psychiatric disorders. J Clin Psychiatry. 1987;48:194-196.